A Look at Receptor–Ligand Pairs for Active-Targeting Drug Delivery from Crystallographic and Molecular Dynamics Perspectives. Gergana Gocheva. Gergana Gocheva. Sofia University “St. Kliment Ohridski”, ...

Delta-like ligand 3 (DLL3), a Notch signaling regulator overexpressed in 70–80% of SCLC tumors, has emerged as a simultaneous biomarker and therapeutic target. This review aims to synthesize recent ...

X-ray photoelectron spectroscopy (XPS) is a nearly universal method for quantitative characterization of both organic and inorganic layers on surfaces. When applied to nanoparticles, the analysis is ...

The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...

A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator’s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge).